Helena H. Chaye
Chief Executive Officer at Western Oncolytics Ltd.
Profile
Helena H.
Chaye is currently the Chief Executive Officer at Western Oncolytics Ltd.
and also holds the position of Chief Executive Officer & Director at Kalivir Immunotherapeutics, Inc. She previously worked as the Director of Business Development at Medigene, Inc. and as the Chief Business Officer at SillaJen Biotherapeutics, Inc. from 2016 to 2018.
She also worked as the Manager of Business Development at Canadian Genetics Diseases Network.
Chaye holds a graduate degree from Dalhousie University and a doctorate degree from the University of British Columbia.
Helena H. Chaye active positions
| Companies | Position | Start |
|---|---|---|
Western Oncolytics Ltd.
 Western Oncolytics Ltd. Pharmaceuticals: MajorHealth Technology Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019. | Chief Executive Officer | 14/08/2019 |
Kalivir Immunotherapeutics, Inc.
 Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Chief Executive Officer | - |
Former positions of Helena H. Chaye
| Companies | Position | End |
|---|---|---|
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/08/2018 |
MediGene, Inc.
 MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Canadian Genetics Diseases Network
 Canadian Genetics Diseases Network Miscellaneous Commercial ServicesCommercial Services Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Training of Helena H. Chaye
| University of British Columbia | Doctorate Degree |
| Dalhousie University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Canadian Genetics Diseases Network
Canadian Genetics Diseases Network Miscellaneous Commercial ServicesCommercial Services Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada. | Commercial Services |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Western Oncolytics Ltd.
Western Oncolytics Ltd. Pharmaceuticals: MajorHealth Technology Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019. | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Health Technology |
- Stock Market
- Insiders
- Helena H. Chaye
